<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146703</url>
  </required_header>
  <id_info>
    <org_study_id>HMC-HO-GI-0501</org_study_id>
    <nct_id>NCT02146703</nct_id>
  </id_info>
  <brief_title>Gemcitabine and S-1 for Advanced Biliary Tract Cancer</brief_title>
  <official_title>Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hallym University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will conduct a phase II study of gemcitabine and S-1 as first-line chemotherapy in
      patient with advanced biliary tract cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biliary-tract cancer (BTC) is invasive carcinoma that originates from the epithelial lining
      of the gallbladder and bile ducts. BTC include cholangiocarcinoma (intrahepatic, perihilar,
      and distal biliary-tree tumor) and carcinoma arising from the gallbladder.

      Surgical resection of the primary tumor is potentially curative for BTC, but less than a
      quarter of patients are eligible for resection at presentation. Systemic chemotherapy is the
      principal treatment method for patients with unresectable or metastatic BTC.

      Gemcitabine is a promising agent, which has shown efficacy in biliary tract cancer. As a
      single-agent therapy, gemcitabine shows response rates of 8-36% in BTC[4]. In phase II trials
      with patients in advanced BTC, gemcitabine in combination with capecitabine or platinum
      analogues produced objective response rates of 26-50%.

      The ABC-02 study reported a significant survival advantage for gemcitabine and cisplatin over
      gemcitabine alone in patients with advanced BTC (median overall survival 11.7 vs. 8.1 months;
      P &lt; 0.001).

      Oral anticancer drug S-1 consists of the 5-FU prodrug tegafur with two biochemical
      modulators, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo). S-1
      monotherapy is active against advanced BTC with objective response rates of 21-35%, and phase
      II trials of S-1 in combination with gemcitabine reported objective response rates of 20-36%.
      Differences between trials in the doses and administration schedules of gemcitabine and S-1
      may be reflected in the ranges of efficacy, dose-intensity, and rates of toxicity observed.

      Even though the efficacy of gemcitabine and S-1 combination is evident for patients with
      advanced BTC in previous phase II trials, there was no clinical study investigating the
      efficacy of gemcitabine and S-1 combination for patients with advanced BTC when this study
      was started. Therefore, we conducted a phase II study to evaluate gemcitabine and S-1
      combination as first-line chemotherapy for patients with advanced BTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective reponse rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, median overall survival, disease control rate, and over grade 3 hematologic toxicities (neutropenia, thrombocytopenia, and febrile neutropenia)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Biliary Tract Neoplasm</condition>
  <arm_group>
    <arm_group_label>gemcitabine and S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, and S-1</intervention_name>
    <description>Treatment will be delivered as a 3-week cycle.
Gemcitabine 1000 mg/m2 iv on day 1, 8
S-1 60 mg/day po on day 1-14</description>
    <arm_group_label>gemcitabine and S-1</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable, locally advanced, metastatic adenocarcinoma arising from the intra- and
             extrahepatic biliary ducts or gallbladder

          -  Initially diagnosed or recurred

          -  At least one bidimensionally measurable lesion, defined as at least 1x1cm with clearly
             defined margins on physical examination, on 3-dimentional CT, MRI, or PET-CT

          -  Age ≥18 and ≤70 years

          -  Estimated life expectancy ≥3 months

          -  ECOG performance status ≤2

          -  Adequate bone marrow function (WBCs ≥4,000/µL or absolute neutrophil count ≥1,500/µL,
             platelets ≥100,000/µL),

          -  Adequate kidney function (creatinine ≤1.4 mg/dL)

          -  Adequate liver function (bilirubin ≤1.8 mg/dL, transaminase levels ≤100mg/dL)

          -  Written informed consent

        Exclusion Criteria:

          -  Other tumor type than adenocarcinoma

          -  Previous history of chemotherapy (exception : adjuvant chemotherapy)

          -  Presence of CNS metastasis, psychosis, or seizure

          -  Obvious bowel obstruction

          -  Evidence of serious gastrointestinal bleeding

          -  Past or concurrent history of neoplasm other than biliary adenocarcinoma, except for
             curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri

          -  Pregnant or lactating women, women of childbearing potential not employing adequate
             contraception

          -  Other serious illness or medical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Young Zang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Oertli D, Herzog U, Tondelli P. Primary carcinoma of the gallbladder: operative experience during a 16 year period. Eur J Surg. 1993 Aug;159(8):415-20.</citation>
    <PMID>8218552</PMID>
  </reference>
  <reference>
    <citation>de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med. 1999 Oct 28;341(18):1368-78. Review.</citation>
    <PMID>10536130</PMID>
  </reference>
  <reference>
    <citation>Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol. 2005;16 Suppl 2:ii93-6. Review.</citation>
    <PMID>15958484</PMID>
  </reference>
  <reference>
    <citation>Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008 Apr;13(4):415-23. doi: 10.1634/theoncologist.2007-0252. Review.</citation>
    <PMID>18448556</PMID>
  </reference>
  <reference>
    <citation>Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.</citation>
    <PMID>20375404</PMID>
  </reference>
  <reference>
    <citation>Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996 Jul;7(5):548-57.</citation>
    <PMID>8862723</PMID>
  </reference>
  <reference>
    <citation>Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004 Nov 15;91(10):1769-74.</citation>
    <PMID>15505626</PMID>
  </reference>
  <reference>
    <citation>Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, Funakoshi A. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008 Oct;62(5):849-55. doi: 10.1007/s00280-007-0673-7. Epub 2008 Jan 23.</citation>
    <PMID>18214482</PMID>
  </reference>
  <reference>
    <citation>Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M. Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2010 May;65(6):1101-7. doi: 10.1007/s00280-009-1115-5. Epub 2009 Aug 26.</citation>
    <PMID>19707761</PMID>
  </reference>
  <reference>
    <citation>Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E. A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34. doi: 10.1007/s00280-010-1443-5. Epub 2010 Sep 2.</citation>
    <PMID>20811895</PMID>
  </reference>
  <reference>
    <citation>Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K. A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer. Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9. doi: 10.1007/s00280-013-2090-4. Epub 2013 Jan 26.</citation>
    <PMID>23355041</PMID>
  </reference>
  <reference>
    <citation>Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, Hamamoto Y, Ishii H, Boku N, Furuse J. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013 Sep;104(9):1211-6. doi: 10.1111/cas.12218. Epub 2013 Jul 25.</citation>
    <PMID>23763511</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biliary tract neoplasm</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>S-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

